Tables S1 to S12 from VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Year: 2023
Type: other
Abstract: Supplementary Table S1. H-scores of ICAM-1, VCAM-1 and IP-10 expression in tumors of melanoma patients before and after ipilimumab or Ipi-Bev treatment. Supplementary Table S2. CXCR3 expression on circulating CD4+ and CD8+ T cells before and after Ipi-Bev treatment. Supplementary Table S3. Pre-treatment serum levels of cytokines/chemokines were not associated with response (CR/PR vs. SD/PD/Uneval) to Ipi-Bev. Supplementary Table S4. Pre-treatment serum levels of cytokines/chemokines were not associated with disease control (CR/PR/SD vs. PD/Uneval) in Ipi-Bev-treated patients. Supplementary Table S5. Fold-changes of serum cytokines/chemokines were not associated with response (CR/PR vs. SD/PD/Uneval) to Ipi-Bev. Supplementary Table S6. Fold-changes of serum cytokines/chemokines were not associated with disease control (CR/PR/SD vs. PD/Uneval) in Ipi-Bev-treated patients. Supplementary Table S7. Response (CR/PR vs. SD/PD/Uneval) to Ipi-Bev by cytokine expression category. Supplementary Table S8. Disease control (CR/PR/SD vs. PD/Uneval) in Ipi-Bev-treated patients by cytokine expression category. Supplementary Table S9. Pre-treatment cytokine levels according to immune related adverse events (irAEs). Supplementary Table S10. Relationship between cytokine fold-changes according to irAEs. Supplementary Table S11. Clinical responses and survival of patients whose plasma samples were used in antibody response analyses. Supplementary Table S12. Effects of ipilimumab alone and Ipi-Bev on circulating cytokine/chemokine levels.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362567153